Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic Sells $3.4M Worth of Synthetic Ligands to Undisclosed Customer

NEW YORK (GenomeWeb News) — ProMetic BioSciences has sold CA$3.9 million ($3.4 million) worth of its mimetic ligand affinity adsorbent product to an “existing multinational” client, the company said today.
 
ProMetic Bio, a division of ProMetic Life Sciences, said it will supply the products in the first and second quarters of 2007.
 
Earlier this month, ProMetic said it would develop synthetic ligands for Novartis' vaccine program.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.